Position in KURA
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$1,097,000
+$284,000 QoQ
Shares Held
100,000
0.0% QoQ
Ownership
0.112%
of shares outstanding
% of Portfolio
0.41%
of 13F equity value
Holder Rank
#76
of 221 holders
Holding Since
Mar 2025
6 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in KURA Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Rosalind Advisors, Inc. holds $173,098,579 across 19 Biotechnology names. KURA ranks #16 (0.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | FENC |
Fennec Pharmaceuticals Inc.
|
3,188,001 | $34,271,010 | |
| 2 | SVRA |
Savara Inc
|
3,178,121 | $19,577,225 | |
| 3 | VSTM |
Verastem, Inc.
|
3,986,509 | $15,228,464 | |
| 4 | XFOR |
X4 Pharmaceuticals, Inc
|
3,214,766 | $15,012,957 | |
| 5 | EYPT |
EyePoint, Inc.
|
988,230 | $14,131,689 | |
| 6 | HELP |
Cybin Inc.
|
1,956,814 | $12,934,540 | |
| 7 | VOR |
Vor Biopharma Inc.
|
648,600 | $11,940,726 | |
| 8 | PCVX |
Vaxcyte, Inc.
|
200,000 | $11,626,000 |
All Filings in KURA
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,097,000 | 100,000 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $813,000 | 100,000 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $1,039,000 | 100,000 | Shares | Sole | 2026-02-12 | |
| 2025-09-30 | $885,000 | 100,000 | Shares | Sole | 2025-11-13 | |
| 2025-06-30 | $577,000 | 100,000 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $660,000 | 100,000 | Shares | Sole | 2025-05-14 | |
| No filing history on record for this holder in this stock. | ||||||